Schemi di intervento nelle forme respiratorie dei bovini da ristallo

Four trials were carried out to investigate the efficiency of gamithromycin in beef cattle's bovine respiratory disease (BRD) prevention and therapy. The gamithromycin is characterized by fast absorption and distribution to target tissue, notably the lung. Three studies were conducted on the preventive efficacy using an untreated control (trial 1), a long-acting oxytetracycline formulation (trial 2) and tulathromycin (trial 3). The responses of tulathromycin and Gamithromycin were compared in the therapeutic study (trial 4). Evaluations included incidence of morbidity, mortality, re-treatments and problem animals (removed to hospitalpen) over the 14 days subsequent to treatment and shortterm growth rates over the first 30 days. Preventive treatment with Gamithromycin significantly reduced the morbidity due to BRD by 86%, 86% and 35% compared to the control groups in trials 1, 2 and 3 respectively. The proportion of problem animals was significantly less in the Gamithromycin group compared to the controls in trial 2. In the therapeutic trial, the incidence of animal that required re-treatment during the 14 days following treatment was 30,8% in the Gamithromycin group, in which there were no problem animals, compared to 81,8% in the positive control group, in which problem animals incidence was 27,7% (significative differences). Growth rates were significantly less in the control animals in trial 1. Overall, these results confirm the usefulness of Gamithromycin in BRD treatment and prevention and provide valuable information about BRD economic balance.